期刊
CANCER CELL
卷 22, 期 1, 页码 7-8出版社
CELL PRESS
DOI: 10.1016/j.ccr.2012.06.009
关键词
-
资金
- NIAID NIH HHS [R01 AI046643] Funding Source: Medline
Negative immune regulatory pathways inhibit anti-cancer T cell responses, preventing effective immune surveillance. Two clinical trials using monoclonal antibodies that antagonize the PD-1/PD-L1 pathway recently reported regression in several tumor types. In one of these trials, efficacy was linked to the expression of the PD-L1 biomarker on tumor cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据